argenx SE and Xencor, Inc.: SG&A Spending Patterns Compared

SG&A Spending Patterns: A Tale of Two Biotechs

In the competitive world of biotechnology, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key differentiator. Over the past decade, argenx SE and Xencor, Inc. have demonstrated contrasting approaches. From 2014 to 2023, argenx SE's SG&A expenses skyrocketed by over 16,000%, reflecting its aggressive expansion and market penetration strategies. In contrast, Xencor, Inc. exhibited a more conservative growth of approximately 615% in the same period.

A Decade of Growth

Starting in 2014, Xencor, Inc. spent modestly, with expenses growing steadily each year. By 2023, their SG&A expenses reached a peak, indicating a strategic shift. Meanwhile, argenx SE's spending surged dramatically, particularly from 2019 onwards, suggesting a robust investment in scaling operations and market presence. This divergence in spending patterns highlights the varied strategies employed by biotech firms to achieve growth and success.